Movatterモバイル変換

[0]ホーム

Jump to content

Oportuzumab monatox

Italiano

Edit links

From Wikipedia, the free encyclopedia

Pharmaceutical drug

Pharmaceutical compound

Oportuzumab monatox
Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized
Target	EpCAM
Clinical data
Other names	oportuzumab monatox-qqrs
ATC code	L01FX16 (WHO)
Identifiers
CAS Number	945228-48-8^N
DrugBank	DB05319^Y
ChemSpider	none
UNII	945CY7ZMI2
KEGG	D11913
Chemical and physical data
Formula	C₃₀₇₂H₄₇₂₃N₈₇₇O₉₅₂S₁₂
Molar mass	69558.48 g·mol⁻¹
^NY (what is this?) (verify)

Oportuzumab monatox is an experimentalanti-cancer medication. Chemically, oportuzumab is asingle chain variable fragment of amonoclonal antibody which binds toepithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused withPseudomonas aeruginosaexotoxin A (which is reflected by themonatox in the medication's name).^[1]

The drug was developed by Canadian-based Viventia Bio Inc. The company was acquired by Cambridge(MA)-based Eleven Biotherapeutics in 2016, which then changed its name to Sesen Bio.^[2]In 2019 Sesen Bio reported updated, preliminary primary and secondary endpoint data from the company's Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicineum for the potential treatment of patients with high-risk, bacillus Calmette-Guérin(BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).^[3] The Company applied for approval of Vicineum by the United StatesFood and Drug Administration and theEuropean Medicines Agency.

References

[edit]

^International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy),World Health Organization.
^Alex Keown:Eleven Biotherapeutics Changes Name to Sesen Bio to Reflect Commitment to Oncology Therapies. Biospace.com, May 16, 2018.
^Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer. Businesswire.com, August 8, 2019

Vol 24, No 18S (June 20 Supplement), 2006: 4580

Targeted cancer therapy /antineoplastic agents (L01)

CI monoclonal antibodies ("-mab")

Receptor tyrosine kinase	ErbB:HER1/EGFR (Cetuximab Panitumumab) HER2/neu (Pertuzumab Trastuzumab (+hyaluronidase) Trastuzumab emtansine Trastuzumab deruxtecan Zanidatamab )
Others for solid tumors	EpCAM (Catumaxomab Edrecolomab) VEGF-A (Bevacizumab)
Leukemia/lymphoma	lymphoid:CD3 (Glofitamab,Elranatamab,Mosunetuzumab),CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab),CD30 (Brentuximab),CD52 (Alemtuzumab) myeloid:CD33 (Gemtuzumab ozogamicin)
Other	Amivantamab Atezolizumab (+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Cosibelimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin Ipilimumab Isatuximab Linvoseltamab Loncastuximab tesirine Mirvetuximab soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab (+hyaluronidase,+relatlimab) Olaratumab Oportuzumab monatox Pembrolizumab (+berahyaluronidase alfa) Penpulimab Polatuzumab vedotin Prolgolimab Ramucirumab Retifanlimab Sabatolimab Sacituzumab govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zenocutuzumab Zolbetuximab

Tyrosine kinase inhibitors ("-nib")

Receptor tyrosine kinase

HER1/EGFR andHER2/neu

BRAF

RTK class III:C-kit andPDGFR (Avapritinib
Axitinib
Masitinib
Pazopanib
Ripretinib
Sorafenib
Sunitinib
Toceranib)
FLT3 (Lestaurtinib,Gilteritinib (AXL, ALK, LTK))

VEGFR

ALK

RET inhibitors:Entrectinib (ALK, ROS1, NTRK),Futibatinib (FGFR2),Infigratinib,Larotrectinib (NTRK),Pemigatinib (FGFR),Pralsetinib,Repotrectinib (ROS1, TRK, ALK),Selpercatinib (VEGFR, FGFR),Taletrectinib (ROS1),Vandetanib (VEGFR, EGFR).

c-MET inhibitors:Cabozantinib (VEGFR),Capmatinib,Crizotinib (ALK)

Non-receptor

bcr-abl

Src (Bosutinib
Dasatinib)

Janus kinase (JAK)

MAP2K (MEK)

EML4-ALK

Bruton's (BTK)

Other

fusion protein againstVEGF (Aflibercept)

proapoptotic peptide againstANXA2 andprohibitin (Adipotide)

exotoxin againstIL-2 (Denileukin diftitox)

mTOR inhibitors

hedgehog inhibitors

CDK inhibitors

KRAS inhibitors
- Adagrasib
- Sotorasib

Pi3K inhibitors

Menin inhibitors
- Revumenib
- Ziftomenib

Fibroblast growth factor receptor (FGFR) inhibitors
Erdafitinib
Futibatinib
Infigratinib
Pemigatinib

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Atezolizumab (+hyaluronidase) Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pembrolizumab^# (+berahyaluronidase alfa) Penpulimab Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisantineoplastic orimmunomodulatory drug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Oportuzumab_monatox&oldid=1235161028"

Categories:

Hidden categories:

[8]ページ先頭